Inhibition of p38 MAPK regulates epileptic severity by decreasing expression levels of A1R and ENT1

XUEJIAO ZHOU1*, QIAN CHEN1*, HAO HUANG1, JUN ZHANG1, JING WANG2, YA CHEN1, YAN PENG1, HAIQING ZHANG1, JUNWEI ZENG3, ZHANHUI FENG4 and ZUCAI XU1

Departments of 1Neurology and 2Prevention and Health Care, Affiliated Hospital of Zunyi Medical University; 3Department of Physiology, Zunyi Medical University, Zunyi, Guizhou 563003; 4Department of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China

Received January 15, 2020; Accepted September 8, 2020

DOI: 10.3892/mmr.2020.11614

Abstract. Epilepsy is a chronic nervous system disease. Excessive increase of the excitatory neurotransmitter glutamate in the body results in an imbalance of neurotransmitters and excessive excitation of neurons, leading to epileptic seizures. Long-term recurrent seizures lead to behavior and cognitive changes, and even increase the risk of death by 2- to 3-fold relative to the general population. Adenosine A1 receptor (A1R), a member of the adenosine system, has notable anticonvulsant effects, and adenosine levels are controlled by the type 1 equilibrative nucleoside transporter (ENT1); in addition, the p38 MAPK signaling pathway is involved in the regulation of ENT1, although the effect of its inhibitors on the expression levels of A1R and ENT1 is unclear. Therefore, in the present study, SB203580 was used to inhibit the p38 MAPK signaling pathway in rats, and the expression levels of A1R and ENT1 in the brain tissue of rats with acute LiCl-pilocarpine-induced status epilepticus was detected. SB203580 decreased pathological damage of hippocampal neurons, prolonged seizure latency, reduced the frequency of seizures, and decreased levels of A1R and ENT1 protein in rats.

Introduction

Epilepsy is one of the most common and serious chronic diseases of the nervous system. According to the World Health Organization, ~70 million individuals currently suffer from epilepsy worldwide (1). The imbalance of excitatory and inhibitory neurotransmission is a common mechanism of epilepsy. Status epilepticus (SE) is a state in which failure of the epileptic termination mechanism or an abnormality of the epileptic initiation mechanism leads to long-term epileptic seizures and requires emergency administration of antiepileptic drugs (2). Failure to terminate SE over time results in neuronal damage and death, and neural network changes (3). Pilocarpine injection can result in SE, which triggers a series of molecular and cellular events that produce neuronal cell death and can culminate in the development of epilepsy (4,5). In a previous study, the p38 signal transduction pathway was activated in kainate-induced status epilepticus and was involved in neuronal damage, moss sprouting, glial cell proliferation and various other changes in the CA1 and CA3 areas of the hippocampus following SE (6). Activation of the p38 pathway can cause damage to hippocampal neurons and increases susceptibility to seizures (7). In addition, the mechanism of p38 signaling pathway may also be associated with its involvement in gliosis following seizures (8). Although there are a number of antiepileptic drugs that can effectively control epileptic seizures, certain cases of seizures cannot be controlled over time, resulting in morbidity and mortality rates ~20% (9). Therefore, exploring the pathophysiological mechanism of SE and providing novel therapeutic targets for antiepileptic drugs are urgently required.

Excessive activity of the excitatory neurotransmitter glutamate results in an imbalance of excitability and inhibition in vivo, causing excessive neuronal excitability, leading to a seizure (10). The anticonvulsant effect of the adenosine system has been confirmed in a number of epilepsy models, suggesting that the adenosine system serves an important role in inhibiting neuronal excitation (11,12). Adenosine has been demonstrated to be an endogenous anticonvulsant and neuroprotective agent in the brain, and its extracellular levels are largely dependent on ectonucleotidase-mediated conversion of ‘activated’ synapse-released ATP and the secretion of astrocytes (13). However, two-way regulation of adenosine levels also depends on type 1 equilibrative nucleoside transporter (ENT1) (13). In addition, the anticonvulsant and neuroprotective effects of adenosine are largely mediated by adenosine A1 receptor (A1R) on the presynaptic membrane (11). The activity-dependent release of adenosine activates A1R to block the release of excitatory transmitters, such as glutamate (14).
Therefore, AIR is an effective molecular and therapeutic target in the course of epileptic seizures (12). Moreover, activated AIR provides a potential endogenous mechanism to inhibit neuronal excitatory activity and seizure dispersion (15).

MAPKs mediate intracellular signaling cascades in response to a variety of stimuli by regulating intracellular gene expression levels, cell division, differentiation, repair and apoptosis (16). MAPKs are activated by extracellular stressors, such as UV light, osmotic pressure, radiation, inflammatory cytokines, growth factors and shock, and subsequently induce a cascade of three kinases to transduce signals (17). Upon stimulation, MAPK kinase kinase is activated by phosphorylation and then phosphorylates and activates MAPK kinase, which in turn phosphorylates and activates MAPK (17). p38 is a MAPK primarily activated by inflammatory factors, stressful stimuli, such as UV light exposure, hypertonic conditions and heat shock, and glutamate (18). Okamoto et al. (19) performed a whole transcriptome analysis of the hippocampi of epileptic rats and observed that p38 MAPK was overexpressed. Our previous study (20) confirmed that the specific p38 MAPK inhibitor SB203580 alleviated epileptic seizures in SE rats. Nitrobenzothioinosine (NBTI), a selective inhibitor of ENT1 (21), blocks the transport of adenosine into cells and increases extracellular adenosine levels, thus exhibiting a protective effect against epileptic seizures (22). A number of studies have revealed that AIR, a member of the adenosine system, has significant anticonvulsant effects (13,23). p38 MAPK affects the levels of ENT1 (24). However, whether the p38 MAPK-specific inhibitor SB203580 regulates the expression levels of AIR and ENT1, and exerts a protective effect during seizures remains unclear.

In the present study, SB203580 was used to inhibit the p38 MAPK signaling pathway in rats. It was observed that SB203580 could reduce the pathomorphological damage of hippocampal neurons, prolong the latency of seizure and reduce the degree of seizure in rats, and reduce the expression of AIR and ENT1.

Materials and methods

**Experimental animals.** In total, 50 healthy adult male Sprague-Dawley (SD) (age, 42-49 days) were purchased from the Experimental Animal Center of Daping Hospital of the Third Military Medical University [license no. scxk (Chongqing, China) 2012-0005]. The rats were provided a standard diet and pure drinking water ad libitum in a room maintained at a constant temperature (24±2°C), and 50-70% humidity. Animal health and behavior were monitored every day; all rats were healthy during the experimental period. The experiment lasted for 2 weeks. All efforts were made to minimize animal suffering. All procedures were approved by the Animal Care and Use Committee of Zunyi Medical University (Zunyi, China).

SD rats (weight, ~180-220 g) were randomly divided into the following 10 groups (5 rats per group): i) Control; ii) NBTI; iii) NBTI + SB203580; iv) SE, 0 h; v) SE, 1 day; vi) SE, 3 days; vii) SE, 7 days; viii) SE, 14 days; ix) SB203580; and x) DMSO. A rat model of acute LiCl-pilocarpine SE was established as described below. Then, randomly selected rats in the SE group received 127 mg/kg LiCl by intraperitoneal (i.p.) injection, followed by 1 mg/kg atropine sulfate i.p. 18-20 h later, then 50 mg/kg pilocarpine i.p. after an additional 30 min. A Racine score of IV-V were recorded (25) to statistical analysis of rat behavior.

For the control rats, instead of the LiCl and pilocarpine administered to the SE group, the same amount of saline was used instead. For rats in the SB203580 group, a solution of the p38 inhibitor SB203580 (15 mg/kg) and 2% DMSO was injected i.p. 30 min prior to injection of pilocarpine (26-28). For rats in the NBTI group, an ENT1 inhibitor (15 mg/kg) (29) was injected i.p. 45 min prior to injection of pilocarpine and 2% DMSO. For rats in the NBTI + SB203580 group, the same protocol was used as aforementioned. For rats in the DMSO group, an equal volume of saline and 2% DMSO was used as a substitution for SB203580.

Euthanasia was accomplished humanely by a trained laboratory personnel via i.p. injection of saline-diluted Euthasol® (150 mg/kg) containing pentobarbital sodium (390 mg/ml) and phenytoin sodium (50 mg/ml), followed by cervical dislocation at the experimental timepoints (0 h, 1, 3, 7 and 14 days). The death of rats was verified using the following criteria: Lack of pulse, breathing and corneal reflex, failure to respond to firm toe pinch, graying of mucus membranes and inability to auscultate respiratory or heart sounds. Following sacrifice of rats, the skull was dissected, brain tissue was removed and the bilateral hippocampus and temporal lobe neocortex were rapidly dissected on ice. Tissue samples were frozen in liquid nitrogen immediately and stored until western blot analysis. After administering complete anesthesia, the control group, SE group and SB203580 group were injected with saline (~150 ml) rapidly and continuously. Then, 4% paraformaldehyde (~150 ml) was injected at room temperature until the limbs, neck and tail became stiff. Then, rats were decapitated and the brain tissue was removed, incubated in 4% paraformaldehyde for 12-24 h (4°C) and sent to the Department of Pathology of Zunyi Medical College to be embedded in paraffin wax and stored at room temperature prior to immunohistochemistry.

Tissues for immunofluorescence and immunohistochemistry were prepared in the same manner. Following decapitation, the brain tissue was placed in successive 20 and 30% sucrose solutions for dehydration at 4°C for 24 h each time; after brain tissue sank, it was sent to the Zunyi Medical College Affiliated Hospital for the preparation of frozen microtome sections (thickness, 16 µm) and stored at -20°C.

**Western blotting.** RIPA buffer and protease inhibitors (Beyotime Institute of Biotechnology) were used to homogenize all samples. The protein concentration of the supernatant was measured with a BCA kit (Beyotime Institute of Biotechnology) according to the manufacturer's instructions. A total of 50 µg protein from each sample was separated via SDS-PAGE (5% separating, 10% stacking gel), and then proteins were transferred to PVDF membranes (250 mA for 100 min). After blocking for 1 h at room temperature in skimmed milk (5%), PVDF membranes were incubated with primary antibodies [rabbit anti-AIR (1:1,000; cat. no. ab82477; Abcam) and mouse anti-β-actin (1:500; cat. no. ab6009-1-ig; ProteinTech Group) and anti-β-tubulin (1:5,000; cat. no. 10094-1-AP; ProteinTech Group)] overnight at 4°C. The blots were washed...
with PBS with 1% Tween-20 (PBST) three times and then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (1:5,000; cat. no. 35105660; Shanghai Yeasen Biotechnology Co. Ltd.) for 1 h at room temperature. Blots were developed using Super Signal West Pico Chemiluminescent HRP substrate (Sigma-Aldrich; Merck KGaA) according to the manufacturer's instructions. Band intensity was analyzed with Quantity One software (Bio-rad laboratories, inc.).

Immunofluorescence. Slides were incubated in acetone at -20°C for 30 min washed in PBS three times for 5 min each, then 0.4% Triton X-100 was added to cover the slices. The slices were placed in a 37°C incubator for 15 min, incubated with PBS three times for 5 min each, immersed in sodium citrate solution, heated at high heat (92-98°C) in microwave oven for 3 min then at 37°C for 10 min, and washed with PBS three times. The brain tissue slices were blocked in 20% goat serum (Beijing Solarbio Science & Technology co., ltd.) for 1-3 h at 37°C, after which the goat serum was discarded. The slides were incubated with rabbit anti-A1R antibody (1:50; cat. no. ab82477; Abcam) and anti-ENT1 antibody (1:50; cat. no. ab223851; Abcam), to which a mixture of mouse anti-glial fibrillary acidic protein (GFAP; 1:100; cat. no. 3670S; Cell Signaling Technology, Inc.) and guinea pig anti-microtubule-associated protein 2 (MAP2) antibody (1:200; cat. no. 188004; Synaptic Systems GmbH) was added. The sliced brain tissue was incubated at 4°C overnight. Then, the brain tissue slices were washed with PBS five times for 5 min each. The slides were incubated with a mixture of DyLight 488-conjugated goat anti-rabbit (1:50; cat. no. 4412S; Cell Signaling Technology, Inc), DyLight 594-conjugated goat anti-mouse (1:200; cat. no. ab96881; Abcam) and DyLight 650-conjugated goat anti-guinea pig antibody (1:50; cat. no. ab102377; Abcam) in a 37°C incubator in the dark for 1 h. The slices were washed with PBS three times for 5 min each in the dark. Following the addition of 50% glycerol solution to cover the slide for storage, pictures were obtained with a laser confocal microscope (magnification, x200) and the slices were stored in the dark.

Immunohistochemistry. Paraffin sections (thickness, 4 µm) were deparaffinized, hydrated with an alcohol gradient and incubated in 0.3% H2O2 for 15 min at room temperature. The sections were incubated for 5 min at 92-98°C in 10 mmol/l sodium citrate buffer and then blocked with 20% goat serum (Beijing Solarbio Science & Technology Co., Ltd.) for 30 min at 37°C. Then, the sections were incubated with rabbit anti-A1R antibody (1:100; cat. no. ab82477; Abcam) at 37°C for 2 h and washed four times with PBS. The sections were then incubated with biotinylated goat anti-rabbit secondary antibody (1:300; cat. no. TA130015; OriGene Technologies, Inc.) at room temperature for 30 min, treated with avidin-biotin complex solution for 30 min at 37°C, washed with PBS and incubated with 3,3'-diaminobenzidine (DAB) (OriGene Technologies, Inc.) for 3 min. Harris' hematoxylin was used for counterstaining at room temperature for 5 min. Images were acquired with an automatic microscope (Nikon Corporation; magnification, x200).

Statistical analysis. Each experiment was repeated at least three times. Data are presented as the mean ± SD and were analyzed using SPSS software (version 18.0; SPSS, Inc.). The behavioral scores of rats (latency of seizures and number of seizures) and results of immunohistochemistry and western

Table I. SB203580 influences the latency of the first seizure and the number of epileptic seizures in rats.

| Group    | Latency of seizures (min) | Number of epileptic seizures, n |
|----------|---------------------------|---------------------------------|
| SE       | 25.89±1.27                | 7.40±1.07                       |
| SB203580 | 37.53±1.73*               | 3.00±0.70*                      |
| DMSO     | 25.65±1.56                | 7.00±0.83                       |

*P<0.05 vs. SE. The number of epileptic seizures was observed continuously for 1 h and is presented as the mean ± SD. SE, status epilepticus.
Results

SB203580 affects the latency of the first seizure and the number of epileptic seizures in rats. Number of seizures was significantly decreased and latency of seizures was prolonged in the SB203580 group compared with the SE group (P<0.05). No differences in these parameters between the DMSO and SE groups were observed (P>0.05) (Fig. 1 and Table I).

AIR expression levels in the hippocampus and temporal lobe neocortex of epileptic rats. The expression levels of AIR in the hippocampus and temporal lobe neocortex of rats were detected by western blotting. The expression levels of AIR were significantly elevated at 1 and 3 days and 7 days after seizure induction. AIR expression levels peaked at 3 days, and were significantly different compared with the control group (P<0.05). No significant differences in the expression levels of AIR at 0 h and 14 days after seizure induction were observed between the control and SE groups (P>0.05). An intervention time point of 3 days was chosen based on changes in AIR expression. Mice were pre-treated with SB203580, then, following 3 days of successful establishment of the epileptic seizure model, the brain tissue was taken for the next experiment, and DMSO was applied as the parallel solvent control. At day 3, AIR was expressed at significantly lower levels in
the SB203580 group than the SE groups (P<0.05), although the difference in A1R expression levels between the DMSO and the SE group was not statistically significant (P>0.05; Fig. 2). Preliminary experiments demonstrated that there was no difference in the expression levels of A1R in the normal, solvent and inhibitor groups at different time points (data not shown).

Immunohistochemical detection of A1R expression levels in the hippocampus and temporal lobe neocortex. Compared with the control group, A1R protein levels in the hippocampus and neocortex of SE rats were elevated. Expression level profiles of A1R in the hippocampus and neocortex were assessed by immunohistochemistry. Positive staining for A1R was primarily detected in neurons located in the hippocampus (CA1 and CA3 regions and the dentate gyrus). In addition, compared with the control group, the percentage of A1R-positive cells was significantly increased in the SE group. The difference in the percentage of A1R-positive cells between the SE and control groups was statistically significant (P<0.05). In addition, the percentage of A1R-positive cells was significantly decreased in the SB203580 group compared with the SE group, and the SB203580 group showed mild staining for A1R (P<0.05; Figs. 3 and 4). There was no significant difference in the percentage of A1R-positive cells between the SE and DMSO groups (P>0.05; Figs. S1 and S2).

Localization of A1R in the hippocampus and temporal lobe neocortex. Immunohistochemical staining for A1R in the hippocampus and temporal cortex showed the expression levels of A1R in the hippocampal neurons of SE rats. The localization of A1R in the hippocampus and neocortex was compared between the control and the SE group (3 days after seizure induction) by multiple immunofluorescence staining. The fluorescence intensity of A1R in the hippocampus (CA1 and CA3 regions) and neocortex was significantly higher in the SE group compared with in the control group (P<0.05). A1R was expressed in cells labeled with dendrite-specific MAP2 but not in cells labeled with astrocyte-specific GFAP (Fig. 5).

Analysis of ENT1 expression levels in the hippocampus and temporal lobe neocortex of epileptic rats by western blotting. Western blotting was used to determine the basal expression levels of ENT1 protein in the hippocampus and temporal cortex of control rats. Compared with the control group, the protein expression levels of ENT1 in the hippocampus and temporal lobe neocortex were significantly increased in the SE group (P<0.05). However, compared with the SB203580 group, the protein expression levels of ENT1 in the hippocampus and temporal lobe neocortex were significantly increased in the SE group (P<0.05). No difference in ENT1 protein expression levels in the hippocampus and temporal lobe neocortex was observed between the DMSO and SE groups (P>0.05) (Figs. 6 and 7).
Effect of the p38 MAPK inhibitor SB203580 on A1R expression levels. The western blotting results showed that A1R expression levels were upregulated in LiCl-pilocarpine SE model rats compared with control rats (P<0.05). By contrast, following administration of the p38 MAPK inhibitor SB203580, A1R expression levels in the SB203580 group were significantly
lower than in the SE group at 3 days after seizure induction (P<0.05). Following administration of the ENTI inhibitor NBTI, the expression levels of A1R in the NBTI group were significantly lower than in the SE group at 3 days after seizure induction (P<0.05).
induction (P<0.05). By contrast, no significant difference in A1R expression levels was observed between the NBTi and SB203580 groups (P>0.05). In addition, following administration of NBTi + SB203580, A1R expression levels were downregulated at 3 days compared with NTi alone. In addition, a significant decrease in A1R expression levels was observed between the NBTi and SB203580 groups (P<0.05; Fig. 8).

Discussion

SE is defined as the occurrence of sustained seizures for >5 min (30). Due to the need for timely termination of SE, delayed intervention of seizures, particularly tonic-clonic seizures, may lead to nervous system injury and death (31). SE is a common, acute and severe neurological disease with high mortality that is characterized by abnormal discharge of various stimuli by highly synchronized neurons in the brain, including neuroinflammation and oxidative stress (32). Seizures are estimated to account for 0.75% of the global disease burden, based on the research in predominantly low-and middle-income countries (33). SE needs to be terminated in a timely manner; the most common and important method is drug therapy (34,35). Currently used antiepileptic drugs primarily inhibit nerve excitation, thereby inhibiting epileptic seizure (36). However, in ~30% of individuals with epilepsy, existing antiepileptic drugs do not control repeated epileptic seizures (36). Therefore, studies aiming to identify novel treatments for patients with epilepsy remain important (37-39).

Adenosine is present in all cells and is involved in controlling the function of all types of tissue and organ. Elevated adenosine levels prevent cell damage and organ dysfunction (40). In addition, adenosine is involved in the adjustment of pathophysiological processes, such as the management of sleep and wakefulness, and affects postsynaptic receptors involved in the release of neurotransmitters (such as glutamate, acetylcholine, thyroxine, serotonin and dopamine) (40). The adenosine system exerts inhibitory effects on the brain; therefore, adenosine is regarded as an endogenous anticonvulsant (15). The anticonvulsant effect of adenosine is primarily mediated by A1R and adenosine A2A receptors, which are in dynamic equilibrium in normal brain tissue and maintain the inhibitory effect of the adenosine system (41). A1R inhibits voltage-gated Ca2+ channels, preventing glutamate release and neuronal depolarization (42). In addition, A1R activates K+ channels to enhance potassium ion outflow, resulting in the hyperpolarization of postsynaptic membrane and reducing the excitability of nerve conduction (43). The adenosine A2A receptor is primarily expressed in the thalamus, where it functions to promote excitatory synaptic transmission and offset the inhibitory effect of A1R upon glutamate release (44). Thus, the adenosine system is regarded as an ‘endogenous antiepilepsy system’ (45).

In the present study, dynamic changes in A1R expression levels following SE were observed in rats. A1R expression levels began to increase 1 day after successful establishment of the SE model and peaked after 3 days before gradually decreasing over 1-2 weeks after seizure induction. Based on the immunohistochemistry results, the number of A1R-positive cells increased and staining for A1R was enhanced in the SE group at 3 days after seizure induction compared with the control group. In the normal brain, A1R and adenosine receptor A2A exhibit a dynamic equilibrium, maintaining the inhibitory effects of the adenosine system. In previous studies in which changes in the expression levels of adenosine receptors in a rat model of the acute phase of epilepsy were examined, A1R was significantly increased 1 day after seizure induction, thus indicating an adaptive response to an acute attack (34,38). However, in patients and animal models of chronic epilepsy, A1R expression levels in brain tissue are downregulated, whereas A2A receptor expression levels are notably upregulated, leading to inhibition of A1R (46). This decrease in A1R expression levels is considered to reflect nerve cell degeneration, and increased extracellular adenosine and A1R expression levels have been revealed to improve the inhibitory effects of the adenosine system until the end of a seizure (15).

In the present study, the seizure onset latency was prolonged and the number of seizures decreased in rats with acute epilepsy treated with the p38 MAPK inhibitor SB203580. SB203580 has previously been demonstrated to selectively inhibit the
activation of p38 MAPK, decrease epileptic seizures in rats and protect CA3 neurons, indicating that the p38 MAPK signaling pathway is involved in an antiepileptic mechanism in the brain (47). In SE, the absence of neurons also increases the expression levels of phosphorylated-p38 and inhibition of p38 MAPK decreases neuronal damage (48). Studies have revealed that the adenosine system activates multiple MAPK signaling pathways via G-protein coupling (49,50). ENT1 is a subtype of a nucleoside transporter and its primary function is to regulate the level of adenosine (51). In the present study, the p38 MAPK inhibitor SB203580 decreased the number of seizures and brain tissue damage, as well as stress-induced endogenous A1R expression levels (Fig. 9).

Numerous types of nervous system disease (including epilepsy, neurodegenerative disease, mental disorders and cerebral blood disease) may involve nucleosides; nucleoside drugs have been designed to treat a range of types of tumors and viral infections (52,53). However, the intracellular and extracellular availability of nucleosides and their derivatives depends on the presence of specific nucleoside transporters (54). Importantly, our previous study found that i.p. and hippocampal injections of nBTi, a selective ENT1 inhibitor, decreased the number of seizures and prolonged the latency of the first seizure in rats, indicating that ENT1 plays an important role in the development of epilepsy (29). Therefore, ENT1 may be a novel therapeutic target for the control of epileptic seizures in the clinic (22,28).

Based on the results of western blot analysis in the present study, ENT1 expression levels 3 days after seizure induction were significantly lower in the SB203580 group than in the epilepsy group, showing that inhibition of the p38 MAPK signaling pathway modified ENT1 expression levels in epileptic rats.

There were certain limitations of the present study. Following SE, the distribution of A1R inside and outside of cells was different from that of normal rats; increased extracellular A1R can protect neurons (55). Secondly, SB203580 was used to inhibit p38 MAPK, but changes in p38 levels following SB203580 application were not detected. Immunohistochemistry demonstrated that the SB203580 group had fewer A1R-positive cells than the SE group; future immunofluorescence experiments should compare the fluorescence intensity of the SE and normal control groups. Moreover, changes in fluorescence intensity of A1R in the SB203580 group require further investigation.

In summary, the results of the present study demonstrated that the p38 MAPK inhibitor SB203580 decreased pathological damage to hippocampal neurons, prolonged the seizure latency and decreased A1R and ENT1 protein expression levels in rats. The proposed antiepileptic effect and protective effects of SB203580 in neurons may be due to decreased ENT1 expression levels, although the specific mechanism requires further investigation.

Acknowledgements

Not applicable.

Funding

The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 81560224 and 81660227) and the Guizhou Provincial Science and Technology Foundation [grant nos. LH (2015) 7520 and LH (2015) 7471].

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

ZX, XZ and QC conceived and designed the study. XZ, QC, YC, HZ and HH performed the experiments. JZh, JW, YP, JZe and ZF conducted statistical analysis, XZ and QC wrote the paper. XZ, QC, HH, JZh, JW, YP, JZe and ZF reviewed and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All procedures were performed in accordance with the Guide for and Use of Medical Laboratory Animals (Ministry of Health of China, 1998) and approved by Animal ethics committee of Zunyi Medical College [approval no. (2016) 2-044].

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Malloka A, Vaillant JD, Soto MT, Viebahn-Hänsler R, Viart ML, Pérez AF, Cedeño RI and Fernández OS: Ozone protective effects against PTZ-induced generalized seizures are mediated by reestablishment of cellular redox balance and A1 adenosine receptors. Neurol Res 37: 204-210, 2015.
2. Lawson T and Yeager S: Status epilepticus in adults: a review of diagnosis and treatment. Crit Care Nurse 36: 62-73, 2016.
3. Sutter R, Semmlack S and Kaplan PW: Nonconvulsive status epilepticus in adults - insights into the invisible. Nat Rev Neuro 12: 281-293, 2016.
4. Córdova-Dávalos L, Carrera-Calvo D, Solís-Navarrete J, Mercado-Gómez OF, Arriaga-Avila V, Agredano-Moreno LT, Jiménez-García LF and Guevara-Guzmán R: Status epilepticus triggers early mitochondrial fusion in the rat hippocampus in a lithium-pilocarpine model. Epilepsy Res 123: 11-19, 2016.
5. Cui Y, Liu J, Luo Y, He S, Xia Y, Zhang Y, Yao D and Guo D: Aberrant connectivity during pilocarpine-induced status epilepticus. Int J Neurol Syst: 1950029, 2020.
6. Xie L, Li T, Song X, Sun H, Liu J, Yang J, Zhao W, Cheng L, Chen H, Liu B, et al: Dynamic alteration of dendrites and dendritic spines in the hippocampus and microglia in mouse brain tissues after kainate-induced status epilepticus. Int J Neurosci: Jun 1, 2020 (Epub ahead of print).
7. Hu JH, Malloy C and Hoffman DA: P38 Regulates kainic acid-induced seizure and neuronal firing via Kv4.2 phosphorylation. Int J Mol Sci 21: E5921, 2020.
8. Che Y, Yu YM, Han PL and Lee JK: Delayed induction of p38 MAPKs in reactive astrocytes in the brain of mice after KA-induced seizure. Brain Res Mol Brain Res 94: 157-165, 2001.
9. Neligan A and Shorvon SD: Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review. Arch Neurol 67: 931-940, 2010.
10. Matute C and Cavaliere F: Neuronal interactions mediated by purinergic signalling in the pathophysiology of CNS disorder. Semin Cell Dev Biol 22: 252-259, 2011.

11. Li Y, Quan C, Feldheim BB, Sisson RP and Boison D: Adenosine dysfunction in neurodegeneration: Cause for seizure generation? Neuron Glia Biol 3: 353-366, 2007.

12. Masino SA, Kawamura M Jr and Ruskin DN: Adenosine receptors and epilepsy: Current evidence and future potential. Int Rev Neurobiol 119: 233-255, 2014.

13. Boison D: Adenosine dysfunction in epilepsy. Glia 60: 1234-1243, 2012.

14. Cunha RA: How does adenosine control neuronal dysfunction and neurodegeneration. J Neurochem. 2016;139(6): 1019-1055.

15. Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH and Patel MK: Adenosine action via spinal cord inflammation at sites of injury. Clin Sci (Lond) 128: 1199-1213, 2015.

16. Ono K and Han J: The p38 signal transduction pathway: A role in adenosine receptor signaling. Cell Signal 12: 1-13, 2000.

17. Downey JS and Han J: Cellular activation mechanisms in septic shock. Front Biosci 3: d468-d476, 1998.

18. Robinson MJ and Cobb MH: Mitogen-activated protein kinase pathways.Curr Opin Cell Biol 9: 180-186, 1997.

19. Okamoto oK, Janjoppi l, Bonone FM, Pansani aP, da Silva aV, Robinson MJ and cobb MH: Mitogen-activated protein kinase pathways. curr opin cell Biol 9: 180-186, 1997.

20. Zhang J, Wang J, et al: A role of p38 MAPK pathway in Epilepsy. J Neurochem 136: 1096-1105, 2016.

21. Matute C and Cavaliere F: Neuronal interactions mediated by purinergic signalling in the pathophysiology of CNS disorder. Semin Cell Dev Biol 22: 252-259, 2011.

22. Masino SA, Kawamura M Jr and Ruskin DN: Adenosine receptors and epilepsy: Current evidence and future potential. Int Rev Neurobiol 119: 233-255, 2014.

23. Boison D: Adenosine dysfunction in epilepsy. Glia 60: 1234-1243, 2012.

24. Cunha RA: How does adenosine control neuronal dysfunction and neurodegeneration. J Neurochem. 2016;139(6): 1019-1055.

25. Rashid K, Van der Zee ce, r oss GM, chapman ca, Stanisz J, Bulavin dV, Phillips c, nannenga B, Timofeev o, donehower la, Huang M, Wang Y, collins M, Gu JJ, Mitchell BS and Graves lM: The role of nucleoside transporters in cancer therapy. Adv Cancer Res 122: 123-1247, 2008.

26. Huicong K, Zheng X, Furong W, Zhouping T, Feng X, Qi H, Xiaoian L, Xiaojiang H, Na Z, Ke X, et al: The imbalanced expression of adenosine receptors in an epilepsy model corrected using targeted mesenchymal stem cell transplantation. Mol Neurobiol 48: 921-930, 2013.

27. Jiang W, Van Cleepput J, Sheerin AH, Ji SP, Zhang Y, Saucier DM, Corcoran ME and Zhang X: Involvement of extracellular regulated kinase and p38 kinase in hippocampal seizure tolerance. J Neurosci Res 81: 581-588, 2005.

28. Cieslak M, Wojtczak A and Kosomszyński M: Role of the purinergic signaling in epilepsy. Pharmacol Rep 66: 335-342, 2014.

29. Sebastião aM and ribeiro Ja: Adenosine receptors and the central nervous system. Handb Exp Pharmacol 193: 471-534, 2009.

30. Fredholm BB: The adenosinergic system and its application for the treatment of CNS diseases. CNS Neurosci Ther 25: 899-910, 2019.

31. Smith Pe: Management of established Status epilepticus. n engl J Med 342: 314-319, 2000.

32. Terrone G, Frigerio F, Balosso S, ravizza T and Vezzani A: Mitogen-activated protein kinase signaling reduces multidrug transporter activity and anti-epileptic drug resistance in refractory epileptic rats. J Neurochem 136: 1096-1105, 2016.

33. Inhibition of p38 MAPK signaling regulates the expression of eaaT2 in the brains of epileptic rats. Front Neurosci 9: 925, 2018.

34. Boison D, Chen JF and Fredholm BB: Adenosine signaling and function in glial cells. Cell Death Differ 17: 1071-1082, 2020.

35. Wagner RG, Bottomley C, ngugi aK, ibinda F, Gómez-olivé FX, Huicong K, Zheng X, Furong W, Zhouping T, Feng X, Qi H, Xiaoian L, Xiaojiang H, Na Z, Ke X, et al: The imbalanced expression of adenosine receptors in an epilepsy model corrected using targeted mesenchymal stem cell transplantation. Mol Neurobiol 48: 921-930, 2013.

36. Liu YJ, Chen J, Li X, Zhou X, Hu YM, Chu SF, Peng Y and Chen NH: Research progress on adenosine in central nervous system diseases. CNS Neurol Ther 25: 899-910, 2019.

37. Shao Y, Wang c, Hong Z and chen Y: Inhibition of p38 mitogen-activated protein kinase signaling reduces multidrug transporter activity and anti-epileptic drug resistance in refractory epileptic rats. J Neurochem 136: 1096-1105, 2016.

38. Boison D: Adenosine as a modulator of brain activity. Drug News Perspect 20: 607-611, 2007.

39. Huang M, Wang Y, Collins M, Gu JJ, Mitchell BS and Graves LM: Inhibition of nucleoside transport by p38 MAPK inhibitors. J Biol Chem 277: 28364-28367, 2002.

40. Rashid K, Van der Zee CE, Ross GM, Chapman CA, Stanisz J, Ropelle RJ, Racine J and Fahnestock M: Adenosine receptor expression of a1r and en T1 in the brain of epileptic rats. Eur J Neurol 12: 1236-1247, 2008.

41. Huicong K, Zheng X, Furong W, Zhouping T, Feng X, Qi H, Xiaoian L, Xiaojiang H, Na Z, Ke X, et al: The imbalanced expression of adenosine receptors in an epilepsy model corrected using targeted mesenchymal stem cell transplantation. Mol Neurobiol 48: 921-930, 2013.

42. Saucier dM, corcoran Me and Zhang X: Involvement of extracellular regulated kinase and p38 kinase in hippocampal seizure tolerance. J Neurosci Res 81: 581-588, 2005.

43. Cieslak M, Wojtczak A and Kosomszyński M: Role of the purinergic signaling in epilepsy. Pharmacol Rep 66: 335-342, 2014.

44. Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH and Patel MK: Adenosine action via spinal cord inflammation at sites of injury. Clin Sci (Lond) 128: 1199-1213, 2015.

45. Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH and Patel MK: Adenosine action via spinal cord inflammation at sites of injury. Clin Sci (Lond) 128: 1199-1213, 2015.

46. Tur M, Quan C, Feldheim BB, Sisson RP and Boison D: Adenosine dysfunction in neurodegeneration: Cause for seizure generation? Neuron Glia Biol 3: 353-366, 2007.

47. Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH and Patel MK: Adenosine action via spinal cord inflammation at sites of injury. Clin Sci (Lond) 128: 1199-1213, 2015.

48. Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH and Patel MK: Adenosine action via spinal cord inflammation at sites of injury. Clin Sci (Lond) 128: 1199-1213, 2015.

49. Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH and Patel MK: Adenosine action via spinal cord inflammation at sites of injury. Clin Sci (Lond) 128: 1199-1213, 2015.

50. Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH and Patel MK: Adenosine action via spinal cord inflammation at sites of injury. Clin Sci (Lond) 128: 1199-1213, 2015.

51. Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH and Patel MK: Adenosine action via spinal cord inflammation at sites of injury. Clin Sci (Lond) 128: 1199-1213, 2015.

52. Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH and Patel MK: Adenosine action via spinal cord inflammation at sites of injury. Clin Sci (Lond) 128: 1199-1213, 2015.

53. Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH and Patel MK: Adenosine action via spinal cord inflammation at sites of injury. Clin Sci (Lond) 128: 1199-1213, 2015.

54. Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH and Patel MK: Adenosine action via spinal cord inflammation at sites of injury. Clin Sci (Lond) 128: 1199-1213, 2015.

55. Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH and Patel MK: Adenosine action via spinal cord inflammation at sites of injury. Clin Sci (Lond) 128: 1199-1213, 2015.